Literature DB >> 8814371

Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party.

F R Macbeth1, J J Bolger, P Hopwood, N M Bleehen, J Cartmell, D J Girling, D Machin, R J Stephens, A J Bailey.   

Abstract

In patients with non-metastatic but inoperable non-small cell lung cancer that is locally too extensive for radical radiotherapy (RT), but who have good performance status, it is important to determine whether thoracic RT should be the minimum that is required to palliate thoracic symptoms or whether treatment should be more intensive, with the aim of prolonging survival. A total of 509 such patients from 11 centres in the UK between November 1989 and October 1992 were admitted to a trial comparing palliative versus more intensive RT with respect to survival and quality of life. They were allocated at random to receive thoracic RT with either 17 Gy in two fractions (F2) 1 week apart (255 patients) or 39 Gy in 13 fractions (F13) 5 days per week (254 patients). Survival was better in the F13 group, the median survival periods being 7 months in the F2 group compared with 9 months in the F13 group, and the survival rates 31% and 36% at one year and 9% and 12% at 2 years, respectively (hazard ratio = 0.82; 95% CI0.69-0.99). There was a suggestion of a trend towards greater benefit in fitter patients. Metastases appeared earlier in the F2 group. As recorded by patients using the Rotterdam Symptom Checklist, the commonest symptoms on admission were cough, shortness of breath, tiredness, lack of energy, worrying and chest pain. These were more rapidly palliated by the F2 regimen. Psychological distress was generally lower in the F13 group. Three patients (two F13, one F2) exhibited evidence of myelopathy. As recorded by patients using a diary card, 76% of the F2 compared with 81% of the F13 patients had dysphagia associated with their RT. This was transient, lasting for a median of 6.5 days in the F2 group compared with 14 days in the F13 group. In conclusion, the F2 regimen had a more rapid palliative effect. In the F13 group, although treatment-related dysphagia was worse, survival was longer.

Entities:  

Mesh:

Year:  1996        PMID: 8814371     DOI: 10.1016/s0936-6555(96)80041-0

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  32 in total

1.  Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

Authors:  R J Stephens; P Hopwood; D J Girling; D Machin
Journal:  Qual Life Res       Date:  1997-04       Impact factor: 4.147

2.  Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy.

Authors:  Yasushi Hamamoto; Masaaki Kataoka; Naoyuki Nogami; Toshiyuki Kozuki; Yuka Kato; Shuichi Shinohara; Tetsu Shinkai
Journal:  Jpn J Radiol       Date:  2012-02-07       Impact factor: 2.374

3.  [Mono- versus polychemotherapy in advanced non-small cell bronchial carcinoma].

Authors:  M Baumann; C Petersen
Journal:  Strahlenther Onkol       Date:  1998-11       Impact factor: 3.621

4.  Palliative Hypofractionated Radiotherapy For Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy: Is It For Many, Some, All, Or None?

Authors:  Timothy D Wagner
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

5.  Palliative Hypofractionated Radiotherapy For Non-small-cell Lung Cancer (NSCLC) Patients Previously Treated By Induction Chemotherapy.

Authors:  George A Plataniotis; Maria-Aikaterini Theofanopoulou; Konstantinia Sotiriadou; Kyriaki Theodorou; Panagiotis Mavroidis; George Kyrgias
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

Review 6.  Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.

Authors:  Rosemary Stevens; Fergus Macbeth; Elizabeth Toy; Bernadette Coles; Jason F Lester
Journal:  Cochrane Database Syst Rev       Date:  2015-01-14

7.  Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study.

Authors:  Aileen B Chen; Angel Cronin; Jane C Weeks; Elizabeth A Chrischilles; Jennifer Malin; James A Hayman; Deborah Schrag
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

8.  Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial.

Authors:  Stephen J Falk; David J Girling; Roger J White; Penelope Hopwood; Angela Harvey; Wendi Qian; Richard J Stephens
Journal:  BMJ       Date:  2002-08-31

9.  Has the practice of radiation oncology for locally advanced and metastatic non-small-cell lung cancer changed in Canada?

Authors:  K Han; A Bezjak; W Xu; G Kane
Journal:  Curr Oncol       Date:  2010-02       Impact factor: 3.677

10.  Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review.

Authors:  N Salvo; S Hadi; J Napolskikh; P Goh; E Sinclair; E Chow
Journal:  Curr Oncol       Date:  2009-03       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.